Johns Hopkins Researchers’ AXT107 May Address Vision Loss

Apr 11, 2019 | Diabetic Macular Edema, Vision


Diabetic macular edema and wet age-related macular degeneration represent the number one cause of vision loss in America with 750,000 people age 40 and older facing diabetic macular edema; and wet age-related macular degeneration impacts over 1.6 million for those 50 and over in the United States.  Blindness is an unfortunate consequence if left untreated.

Johns Hopkins-based researchers have developed a new compound called AXT107.  Research involving lab-grown human cells and mice, reveal that the investigational drug may be exceptionally good at fighting vision loss.  In fact, it stops abnormal blood vessels from leaking vision-impeding fluids.  Previous investigations into the compound evidenced the preclusion of abnormal vessels in preclinical animal studies involving diabetic macular edema and wet age-related macular degeneration.

Presently, the standard of care involves monthly injections into the eye to impede new blood vessel growth. The constant injections represent a burden plus risks include infection and logistical concerns for patients. Investigators are seeking a superior treatment and perhaps AXT107 represents the answer.  AXT107 provides a potentially more effective approach to treat these diseases. The Johns Hopkins researchers plan to test AXT107 peptide for safety and efficacy in a clinical research program with a focus first on diabetic edema in coming year.

Lead Research/Investigator

Aleksander Popel, PhD, professor of biomedical engineering

Adam C. Mirando 


Pin It on Pinterest